PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Cash & Equivalents	15.17	50.18	68.04	85.4	2.2
Short-Term Investments	0.37	-	-	-	-
Cash & Short-Term Investments	15.54	50.18	68.04	85.4	2.2
Cash Growth	-69.03%	-26.25%	-20.33%	3778.14%	146.08%
Other Receivables	3.7	-	-	-	-
Receivables	3.7	-	-	-	-
Prepaid Expenses	0.22	0.26	0.11	0.09	0.07
Other Current Assets	2.92	-	-	-	-
Total Current Assets	22.38	50.44	68.15	85.49	2.28
Long-Term Investments	22.47	-	1.57	1.57	1.57
Other Intangible Assets	1.55	1.55	3.55	3.55	3.55
Other Long-Term Assets	8.77	7.91	0.01	0.01	0.01
Total Assets	55.17	59.9	73.28	90.62	7.4
Accounts Payable	0.4	0.39	0.13	0.21	0.17
Accrued Expenses	2.52	0.74	0.46	0.5	0.5
Short-Term Debt	-	-	-	-	0.05
Other Current Liabilities	-	0.46	-	-	-
Total Current Liabilities	2.91	1.59	0.59	0.7	0.72
Other Long-Term Liabilities	0.36	12.97	-	-	-
Total Liabilities	3.28	14.56	0.59	0.7	0.72
Common Stock	0	0	0	0	0
Additional Paid-In Capital	181.49	185.33	202.23	201.58	114.11
Retained Earnings	-84.97	-115.63	-115.96	-111.65	-107.41
Treasury Stock	-44.61	-42.04	-13.56	-	-
Comprehensive Income & Other	-0.02	-0.02	-0.02	-0.02	-0.02
Total Common Equity	51.89	27.65	72.69	89.92	6.68
Shareholders' Equity	51.89	45.35	72.69	89.92	6.68
Total Liabilities & Equity	55.17	59.9	73.28	90.62	7.4
Total Debt	-	-	-	-	0.05
Net Cash (Debt)	15.54	50.18	68.04	85.4	2.15
Net Cash Growth	-69.03%	-26.25%	-20.33%	3869.72%	204.54%
Net Cash Per Share	2.12	5.24	3.49	5.50	1.49
Filing Date Shares Outstanding	6.8	7.71	8.78	20.75	1.61
Total Common Shares Outstanding	6.8	8.04	16.79	20.72	1.59
Working Capital	19.46	48.85	67.56	84.79	1.55
Book Value Per Share	7.64	3.44	4.33	4.34	4.20
Tangible Book Value	50.34	26.1	69.14	86.37	3.13
Tangible Book Value Per Share	7.41	3.25	4.12	4.17	1.97

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q